Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

In this Healio Video Perspective from Telling It Like It Is, Cynthia Matossian, MD, FACS, shared pearls for ophthalmologists ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...

February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Dr Bahl said ICMR will support the development of newer therapies such as gene therapy and help take them to the market.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...